David VanderWeele

10PUBLICATIONS
107CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 29, 2026
Clinical and Molecular Profiles of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancers in the Era of Intensified Systemic Therapies.

|Mar 25, 2026
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Emmanuel S Antonarakis, Qing Cao, Victoria Catharine

|Jan 13, 2026
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Surendra Gulla, Tej Sharma, Ephraim Gardner

|Nov 20, 2025
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.

Deaglan McHugh, Matthew Dallos, Min Yuen Teo

|Mar 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.

Rahul R Aggarwal, Jacqueline Vuky, David VanderWeele

|Mar 10, 2025
Response to pembrolizumab in advanced prostate cancer with predictive biomarkers.

Nicole J Altomare, Yutai Li, Clayton Neill

Pageof 2

Frequent Collaborators

3 joint publications

Fatima Karzai

2 joint publications

Remi Adelaiye-Ogala

2 joint publications

Emmanuel S Antonarakis

2 joint publications

Ravi A Madan